Previously Treated Metastatic Non-Small Cell Lung Cancer
Conditions
Keywords
Non-small cell lung cancer
Brief summary
The purpose of this study is to determine the response rate to treatment with oxaliplatin and Navelbine in patients with previously treated NSCLC. Oxaliplatin and Navelbine have not been clinically evaluated yet. However, Navelbine has been safely administered with other platinum compounds.
Detailed description
This is a non-randomized trial for patients with previously treated Non-small cell lung cancer. Each patient will receive 6 cycles of chemotherapy consisting of Oxaliplatin and Navelbine. Oxaliplatin is given intravenously every 21 days and Navelbine is administered Intravenously on day 1 and day 8 every 21 days.
Interventions
DRUGOxaliplatin
Sponsors
Sanofi
Integrated Community Oncology Network
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Locally advanced or metastatic non-small cell lung cancer that has recurred, progressed, or failed to respond to previous systemic chemo. * Measurable disease * Good performance status (ECOG 0,1 or 2)
Exclusion criteria
* Previously treated with Oxaliplatin or Navelbine * Symptomatic CNS metastases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to progression | — |
| Duration of response | — |
| Survival | — |
| Toxicity profile | — |
Countries
United States
Contacts
Primary ContactDiane L Edwards, RN,OCN, CCRP
Backup ContactGloria Perez, RN, BSN, CCRP
Outcome results
None listed